Fig. 7From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsDuration until resistance acquisition under irreversible EGFR TKI therapy. Duration until resistance acquisition under irreversible EGFR TKI therapy in dependence on primary driver mutation (a) and p.T790M acquisistion status (b) respectively and combined (c). n.s. =no statistical significance (determined by student’s t-test)Back to article page